跳至主要内容
临床试验/NCT02511561
NCT02511561已完成2 期

A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration for Treatment of Otitis Externa

Otonomy, Inc.1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2015年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Otonomy, Inc.
入组人数
75
试验地点
1
主要终点
Otoscopic Examination: Tympanic Membrane

研究概览

简要总结

This is a 1-month, multicenter, open-label study in subjects with unilateral otitis externa. Eligible subjects will receive a single dose of 6 mg OTO-201 to the affected ear. The study is designed to characterize safety, procedural factors and clinical effect of OTO-201 administered in subjects with otitis externa.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Months 至 80 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

0.1 mL OTO-201

Experimental

Ciprofloxacin

干预措施: OTO-201 (ciprofloxacin) (Drug)

0.2 mL OTO-201

Experimental

Ciprofloxacin

干预措施: OTO-201 (ciprofloxacin) (Drug)

0.4 mL OTO-201

Experimental

Ciprofloxacin

干预措施: OTO-201 (ciprofloxacin) (Drug)

结局指标

主要结局

Otoscopic Examination: Tympanic Membrane

时间窗: Up to 1 month

Number of subjects with a tympanic membrane that was rated as "Not able to Visualize" or "Abnormal" at Baseline that was rated as "Normal" at Day 29 (final study day)

Otoscopic Examination: Middle Ear

时间窗: Up to 1 month

Number of subjects with a middle ear that was rated as "Not Able to Visualize" or "Abnormal" at Baseline that had a middle ear rated as "Normal" at Day 29 (final study visit)

Feasibility of Administration

时间窗: Day1

Ease of administering OTO-201 to the external ear canal. Number of subjects that investigators rated ease of administration as either "easy" or "very easy".

Overall Adverse Events

时间窗: up to 1 month

Number of Subjects with and without adverse events during the study from dosing up to 1 month after dosing

次要结局

  • Number of Subjects Considered a Clinical Cure at Day 15 (Intent-to-treat Analysis Set)(Day 15 (two weeks from dosing))
  • Number of Subjects Considered a Clinical Cure at Day 15 (Per-protocol Analysis Set)(Day 15 (2 weeks from dosing))

研究者

发起方
Otonomy, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验